Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
3.
Neuropsychiatr Dis Treat ; 14: 1139-1142, 2018.
Article in English | MEDLINE | ID: mdl-29765217

ABSTRACT

A 73-year-old man, exhibiting psychomotor excitement after traumatic brain injury, developed allergic cutaneous eruptions and hepatic inflammation that did not resolve after the cessation of carbamazepine (CBZ). Fusing maculopapular erythema was observed in the face, neck, presternal region, and bilaterally in the forearms and feet. A drug-induced lymphocyte stimulation test revealed hypersensitivity to chlorpromazine (CPZ) and valproic acid (VPA), as well as to CBZ. The allergic reaction with eosinophilia to CPZ and VPA was suspected to have emerged following CBZ hypersensitivity, since previous treatment with CPZ and VPA prior to the introduction of CBZ had not been associated with adverse reactions earlier in the course of treatment. Recent studies have indicated linkages between severe CBZ hypersensitivity - but not mild CBZ hypersensitivity - and specific leukocyte antigens, HLA-B*1502 and HLA-A*3101, in Asian and European populations. The present case exhibited the HLA-B*4601 allele, which is associated with a high relative risk for the development of CBZ-induced maculopapular eruptions in Japanese and Han Chinese populations. Although cross-hypersensitivity among aromatic compounds, including CBZ and CPZ, is well-established, data regarding CBZ allergy-associated hypersensitivity to VPA are limited. In the present case, a cutaneous allergy to mianserin (a tetracyclic antidepressant) was also observed later in the course of treatment, suggesting additional cross-reactivity exists among aromatic psychotropic drugs. Thus, the association between the HLA-B*4601 allele and allergic reactions to VPA, aromatic psychotropic drugs, and CBZ should be further examined in future studies.

6.
J Dermatol ; 44(11): 1303-1308, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29098727

ABSTRACT

We report a case of bilateral annular breast keloids in a 72-year-old woman who had been suffering from bilateral breast cancers. Histopathologically, the keloids showed unique distribution of α-SMA+, CD34- myofibroblasts and α-SMA-, CD34+ fibroblasts depending on the region. High serum levels of tumor growth factor-ß were detected at 6 months after the development of the breast keloids, but not at 10 months. CD163-positive cells were abundantly detected in the skin of the elevated portion of the keloids. In contrast, these cells were considerably less numerous in the skin of the central healing portion compared with the skin of the elevated expanding portion. One interesting idea based on these results is that high levels of tumor growth factor-ß released from CD163-positive cells played a crucial role in the formation of breast keloids through active induction of fibroblast differentiation into myofibroblasts. The present case strongly supports the previously proposed idea that keloids can form as a paraneoplastic phenomenon in breast cancer patients with keloid constitution.


Subject(s)
Breast Neoplasms/complications , Keloid/etiology , Aged , Female , Humans , Keloid/blood , Keloid/pathology , Lymphotoxin-alpha/blood , Skin/pathology
8.
J Dermatol ; 44(8): 954-958, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28295566

ABSTRACT

Concomitant confluent and reticulated papillomatosis (CRP) and acanthosis nigricans (AN) is rare. We present a case of concomitant CRP and obesity-associated AN in a 12-year-old obese Japanese girl. Curiously, oral minocycline therapy, which has been shown to be effective for CRP, was effective against both CRP and AN. Possible mechanisms by which minocycline could have improved skin lesions of CRP and obesity-associated AN are discussed. In addition, reports of concomitant CRP and obesity-associated AN are reviewed. CRP and obesity-associated AN share common clinicopathological features and some reports have described concomitant CRP and obesity-associated AN. Together with the observation that skin lesions of CRP and obesity-associated AN in the present case responded to oral minocycline therapy, these facts suggest a tight relationship or a common pathogenetic pathway between these pathologies.


Subject(s)
Acanthosis Nigricans/drug therapy , Insulin Resistance , Obesity/drug therapy , Papilloma/drug therapy , Rare Diseases/drug therapy , Skin Neoplasms/drug therapy , Acanthosis Nigricans/blood , Acanthosis Nigricans/complications , Alkaline Phosphatase/blood , Anti-Bacterial Agents/therapeutic use , Biopsy , Blood Glucose/analysis , C-Peptide/blood , Child , Female , Humans , Minocycline/therapeutic use , Obesity/blood , Obesity/complications , Papilloma/blood , Papilloma/pathology , Rare Diseases/blood , Rare Diseases/complications , Rare Diseases/pathology , Skin/pathology , Skin Neoplasms/blood , Skin Neoplasms/pathology , Syndrome , Treatment Outcome
9.
Allergol Int ; 60(3): 277-81, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21364312

ABSTRACT

BACKGROUND: The majority of patients with cholinergic urticaria presents with strong hypersensitivity to autologous sweat. Patients with severe cholinergic urticaria are frequently resistant to H(1) antagonists which are used in conventional therapies for various types of urticaria. It has been reported that desensitization using partially purified sweat antigen was effective in a patient with cholinergic urticaria. METHODS: The aim of this study is to determine the usefulness of rapid desensitization with autologous sweat in severe cholinergic urticaria, because rapid desensitization has proven to be a quick and effective immunotherapy for allergies to various allergens. Six patients with severe cholinergic urticaria who are resistant to H(1) antagonists and have sweat hypersensitivity were enrolled in a rapid desensitization protocol. RESULTS: In all six patients, the responses for skin tests with autologous sweat were attenuated after rapid desensitization with autologous sweat. Two of the three cholinergic urticaria patients showed reduced histamine release with autologous sweat after the rapid desensitization with autologous sweat. Further, the rapid desensitization and subsequent maintenance treatment reduced the symptoms in five of the six patients. CONCLUSIONS: This study provides evidence that rapid desensitization with autologous sweat is beneficial for treating cholinergic urticaria patients resistant to conventional therapy who have sweat hypersensitivity.


Subject(s)
Desensitization, Immunologic , Sweat/immunology , Urticaria/therapy , Adolescent , Adult , Female , Histamine Release/immunology , Humans , Middle Aged , Skin Tests , Treatment Outcome , Urticaria/immunology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...